The present invention relates to a compound represented by the general formula (I): ##STR00001## wherein m.sub.1 and m.sub.2 are 1, 2, or 3; n.sub.1 and n.sub.2 are 0 or 1; i is an integer of any of 1 to m.sub.1; j is an integer of 1 to m.sub.2; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; R.sub.ai and R.sub.ai' is hydrogen atom, etc. and R.sub.bj and R.sub.bj' is hydrogen atom, etc.; R.sub.c, R.sub.d, and R.sub.e are hydrogen atom, etc; X.sub.1 is CH, CX.sub.1a, or N; X.sub.2 is CH, N, etc.; X.sub.3 is CH, N, etc.; X.sub.4 is CH or N; Y.sub.1, Y.sub.2, and Y.sub.3 are each independently CH or N; Z.sub.1 and Z.sub.2 are each independently CH or N; W is a 5-membered aromatic heterocyclic group such as pyrazolyl, thiazolyl, etc., or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition or antitumor agent containing the same; and combinations of the antitumor agent with other antitumor agent(s).

 
Web www.patentalert.com

< Isolated polypeptide comprising a leptin fragment

> N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-- pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor

~ 00499